Author

R. Petremand

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Organism:human· 2 Assay:scRNA-seq· 2 Research Focus:clustering· 1 Approach:deep learning· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Harari· 2 shared A. Orcurto· 2 shared D. Barras· 2 shared D. Dangaj Laniti· 2 shared E. Ghisoni· 2 shared F. Benedetti· 2 shared G. Coukos· 2 shared I. Crespo· 2 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Harari

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 21, 2023

Tumor-reactive clonotype dynamics underlying clinical response to TIL therapy in melanoma

J. Chiffelle, D. Barras, R. Petremand…·G. Coukos

This study tracks tumor-reactive TIL clonotypes in melanoma patients before and after TIL-ACT to identify factors associated with clinical response.

DOI 10.1101/2023.07.21.544585

𝕏 PostBluesky

ImmunologybioRxivPreprintDec 23, 2022

Tumor Microenvironment Cellular Crosstalk Predicts Response to Adoptive TIL Therapy in Melanoma

D. Barras, E. Ghisoni, J. Chiffelle…·G. Coukos

This study identifies CD8+ TIL-myeloid cell networks as predictors of response to adoptive TIL therapy in melanoma using single-cell RNA-seq and spatial proteomic analyses.

DOI 10.1101/2022.12.23.519261

𝕏 PostBluesky